Johnson & Johnson Vaccine Provides Protection Against Delta Variant

The Johnson & Johnson single-dose vaccine can now provide immunity against COVID-19 for at least eight months, as well as protection against "other highly prevalent SARS-CoV-2 viral variants" of the virus.

The company announced on Thursday that during its trial, the vaccine generated a "strong neutralizing antibody response" to the widely spreading Delta variant, with 85% effectiveness.

Notably, the Delta variant is currently the greatest threat in the U.S. several cases have been discovered in parts of India as well.